C3i Center Inc., a contract development and manufacturing organizations (CDMO), is manufacturing a cell therapy product for Europe that is currently in phase II clinical trials.

C3i Center Inc. offers full in-house services for the development and commercialization of cell and gene therapies, including CRO, regulatory, Qc testing, biomarker development and immune monitoring services for Canada, the U.S., and Europe. C3i manufactures from process development to phase 3 with the expected goal of commercial manufacturing launch end of 2024. C3i has experience in autologous and allogeneic therapies using viral and non-viral methods as well as editing using CRISPR-based technologies.

“We are proud of our team has worked very hard to be able to manufacture for EU clinical sites from our Montreal facility here in Canada. We already manufacture cell therapies destined for clinical sites in the United States and Canada and are pleased to be able to expand our capabilities to include Europe,” said Louisa Petropoulos, CEO of C3i Center Inc. “We are looking forward to continue to work in partnership with our clients, ensuring that we help them through the product development chain, clinical testing milestones and supporting them all the way to commercialization.”